X
skip to main content
Logo
media conference

Press Releases

  • May 24, 2017

    Understanding why some prostate cancer tumours are indolent while others eventually kill patients is the focus of many within the global cancer research community. A top Canadian research team has provided new answers with the potential to change the way aggressive tumours are treated and, importantly, improve cure rates.

  • May 24, 2017

    The use of oncolytic viruses to stimulate a patient’s immune system as well as directly kill tumour cells is a novel approach to eradicating cancer, but antibodies that permanently inactivate the virus are often generated that counter treatment efficacy. An Ottawa-based lab has come up with a way of countering this problem by using a complement inhibitor that prevents the virus’ neutralization, thereby ensuring viral vectors reach their target.

  • May 18, 2017

    The finding by a B.C. team studying rare and forme fruste tumours is important in that it may help to identify women at risk of relapse for the disease, as well as to provide a non-invasive way to monitor patients in follow-up.

  • May 17, 2017

    An article published in The National Post in mid-May has identified the Terry Fox Foundation as one of the best places to donate to cancer research in Canada.

  • April 25, 2017

    Awards to four New Investigators were recently made, with each award valued at $450,000 for a term of three years. Recipients are: Dr. Housheng Hansen He (UHN), Dr. Frédérick Mallette (UdeM), and Dr. Peter Stirling (BC Cancer Agency), and Dr. Trevor Pugh.

  • March 24, 2017

    TFRI New Investigator Paul Boutros is among a team of researchers who have found a new test that can help to determine men at high risk for aggressive prostate cancer. The findings, published in The Journal of the National Cancer Institute, could help fill an unmet need for reliable genetic testing for prostate cancer from a simple blood sample.

  • February 15, 2017

    New Brunswick-led national research team aims for tailored treatments for patients with incurable multiple myeloma through Terry Fox Research Institute's $5-million investment.

  • February 15, 2017

    In the House of Commons today, Cambridge MP Bryan May congratulated TFRI and its joint pilot project partners -- The Princess Margaret Cancer Centre and the BC Cancer Agency -- for their new partnership to accelerate precision medicine. You can listen to his remarks on You Tube or read them below.

  • February 02, 2017

    The Terry Fox Research Institute and two leading cancer centres in Canada -- the Princess Margaret Cancer Centre and the BC Cancer Agency -- have launched an innovative pilot project to accelerate precision medicine for their cancer patients.

  • January 04, 2017

    A biomarker study by COEUR (Canadian Ovarian Experimental Unified Resource), TFRI’s pan-Canadian ovarian cancer research team, examining over 2,000 ovarian cancer tissue samples has led to the development of an inexpensive immunohistochemical algorithm for classifying the five different disease subtypes.

  • January 03, 2017

  • January 03, 2017

    A study by TFRI researchers investigating potential new drugs to treat glioblastoma (GBM) patients has identified an epigenetic-modifier drug which, taken in combination with standard chemotherapy, extends life in mouse models. Further, a second inhibitor that limits tumour growth and shows no toxicity to cells may also hold promise as a treatment therapy.

  • January 03, 2017

    When it comes to treating prostate cancer, the news is predominantly positive: a combination of early detection and treatment by radiotherapy and surgery mean that most patients will not die of the disease. Still, its incidence continues to rise and prostate cancer remains the most frequently diagnosed non-skin malignancy in Canadian men.

  • January 03, 2017

  • January 03, 2017

    A study by a TFRI-funded team based at the Vancouver Prostate Centre has found that silencing a key driver of castrate-resistant prostate cancer and regulating cell division (mitosis) can improve patient drug response.

Back to Top